 |
市場調查報告書
商品編碼
2076125
神經性眼痛市場：依藥物類別、通路和地區分類Neuropathic Ocular Pain Market, By Drug Class, By Distribution Channel, And by Region |
||||||
價格
簡介目錄
預計到 2026 年，神經性眼痛市場規模將達到 2.166 億美元，到 2033 年將達到 2.724 億美元。預計從 2026 年到 2033 年，該市場將以 3.3% 的複合年成長率成長。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2025 | 2026年市場規模： | 2.166億美元 |
| 歷史數據時期： | 2020年至2024年 | 預測期： | 2026年至2033年 |
| 2026年至2033年預測期間的複合年成長率： | 3.30% | 2033年市場規模預測： | 2.724億美元 |
神經性疼痛是一種以慢性疼痛為特徵的疾病。雖然它通常由慢性進行性性神經系統疾病引起，但也可能由外傷或感染疾病導致。眼部神經病變疼痛（也稱為角膜神經病變疼痛）是指角膜對通常無痛的刺激產生疼痛反應的疾病。這是由於角膜神經反覆受到直接傷害所致。受損的神經即使在沒有疼痛刺激的情況下也會向中樞神經系統 (CNS) 發送疼痛訊號，因此被稱為「無刺激性疼痛」或「幻覺性角膜」。這種情況相當於全身性神經病變疼痛、複雜性局部疼痛症候群或反射性交感神經營養不良 (RSD) 的眼部版本。眼部或角膜神經病變疼痛、角膜神經病變、角膜神經病變、角膜神經痛和角膜異位痛等名詞均用於描述同一疾病。
市場動態
政府和非政府組織加強改善民眾獲得可負擔眼科醫療服務的機會，以及公眾對眼科疾病的認知不斷提高，預計將推動市場成長。此外，主要市場參與者推出更多新產品預計也將促進預測期內的市場成長。例如，2021年11月，私人公司眼科護理公司I-MED Pharma宣佈在美國推出其全系列乾眼症治療產品。 「I-DROP」和「I-DEFENCE」等產品旨在長期緩解神經性眼痛引起的乾眼症狀。
本研究的主要特點：
- 本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
- 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
- 本研究根據以下參數對全球神經性眼痛市場的主要參與者進行了分析：公司概況、產品系列、主要亮點、財務表現和策略。
- 本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
- 這份「全球神經性眼痛市場」報告旨在為產業內的各類相關人員提供參考，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
- 相關人員可以透過利用全球神經性眼痛市場分析中使用的各種策略矩陣來簡化決策過程。
目錄
第1章：研究目標與前提條件
- 分析目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章：市場動態、監管與趨勢分析
- 市場動態
- 促進因素
- 抑制因子
- 市場機遇
- 影響分析
- 近期產品發布
- 流行病學
- 併購和合作
- 監管趨勢
- 主要進展
- PEST分析
- 管道分析
第4章 全球神經性眼痛市場：依藥物類別分類，2021-2033年
- 概述
- 類固醇
- 非類固醇消炎劑
- 抗憂鬱症
- 抗驚厥藥物
- 鴉片類藥物
- 其他（維生素B補充劑、A型肉毒桿菌等）
第5章 全球神經性眼痛市場：依通路分類，2021-2033年
- 概述
- 醫院藥房
- 零售藥房
- 網路藥房
第6章 全球神經性眼痛市場：依地區分類，2021-2033年
- 概述
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
- 歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
- 中東
- GCC
- 以色列
- 其他中東國家
- 非洲
- 北非
- 中非
- 南非
第7章 競爭情勢
- OKYO Pharma, Limited
- Ocular Therapeutix, Inc.
- IACTA Pharmaceuticals, Inc.
- Sun Pharmaceutical Industries Ltd.
- Novartis AG
- SALVAT
- AbbVie Inc.
- Bausch & Lomb Incorporated
- Kala Pharmaceuticals
- Spectra Vision Care
- Alcon Laboratories
- AERIE PHARMACEUTICALS, INC.
- Optocred Pharmaceuticals
- BRIM Biotechnology, Inc.
第8章
- 調查方法
- 關於本公司
簡介目錄
Product Code: CMI5600
Neuropathic Ocular Pain Market is estimated to be valued at USD 216.6 Mn in 2026 and is expected to reach USD 272.4 Mn by 2033, growing at a compound annual growth rate (CAGR) of 3.3% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 216.6 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 3.30% | 2033 Value Projection: | USD 272.4 Mn |
Neuropathic pain is a pain condition that's usually chronic. It's usually caused by chronic, progressive nerve disease, and it can also occur as the result of injury or infection. Ocular neuropathic pain, also referred to as corneal neuropathic pain, is a condition where corneal pain is seen in response to normally non-painful stimuli. This results from repeated direct damage to corneal nerves. This damaged nerve sends pain signals to central nervous system (CNS) even in the absence of painful stimulus, thus, called "pain without stain" or "phantom cornea'. This condition is the ocular analog of systemic neuropathic pain, a complex regional pain syndrome, or reflex sympathetic dystrophy (RSD). Ocular or corneal neuropathic pain, corneal neuropathy, corneal neuralgia, kertaoneuralgia, and corneal allodynia are all terms that are used to describe the same disease entity.
Market Dynamics
An increase in government and non-government organizations' initiatives to improve access to affordable vision care and an increase in awareness among people regarding eye-related disease are expected to drive the market growth. Moreover, an increase in product launches by key market players is expected to drive the market growth over the forecast period. For instance, in November 2021, I-MED Pharma inc., a privately held Canada based eye care company, announced that it had launched an entire portfolio of dry eye products in the U.S. The products such as I-DROP, I-DEFENCE, and others, are intended to provide long-lasting relief from eye dryness, which is caused due to neuropathic ocular pain.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global neuropathic ocular pain market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include OKYO Pharma, Limited, Ocular Therapeutix, Inc., IACTA Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., Novartis AG, SALVAT, AbbVie Inc., Bausch & Lomb Incorporated, Kala Pharmaceuticals, Spectra Vision Care, Alcon Laboratories, AERIE PHARMACEUTICALS, INC., Optocred Pharmaceuticals and BRIM Biotechnology, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global neuropathic ocular pain market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neuropathic ocular pain market
Detailed Segmentation:
- Global Neuropathic Ocular Pain Market, By Drug Class (Revenue, USD Mn, 2021 - 2033)
- Steroids
- Non-Steroidal Anti-Inflammatory Drugs
- Antidepressants
- Anticonvulsants
- Opioids
- Others (Vitamin B supplements, Botulinum toxin A, and others)
- Global Neuropathic Ocular Pain Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Neuropathic Ocular Pain Market, By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- By Country:
- U.S.
- Canada
- By Country:
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country:
- Europe
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Country:
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Country
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Country:
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Country/Region:
- Company Profiles
- OKYO Pharma Limited*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Ocular Therapeutix, Inc.
- IACTA Pharmaceuticals, Inc.
- Sun Pharmaceutical Industries Ltd.
- Novartis AG
- SALVAT
- AbbVie Inc.
- Bausch & Lomb Incorporated
- Kala Pharmaceuticals
- Spectra Vision Care.
- Alcon Laboratories
- AERIE PHARMACEUTICALS, INC.
- Optocred Pharmaceuticals
- BRIM Biotechnology, Inc.
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
- Pipeline Analysis
4. Global Neuropathic Ocular Pain Market, By Drug Class, 2021 - 2033, (US$ Million)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Steroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Non-Steroidal Anti-Inflammatory Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Antidepressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Anticonvulsants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Opioids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Others (Vitamin B supplements, Botulinum toxin A, and others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
5. Global Neuropathic Ocular Pain Market, By Distribution Channel, 2021 - 2033, (US$ Million)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
6. Global Neuropathic Ocular Pain Market, By Region, 2021 - 2033, (US$ Million)
- Overview
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (US$ Million)
- North Africa
- Central Africa
- South Africa
7. Competitive Landscape
- OKYO Pharma, Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Ocular Therapeutix, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- IACTA Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- SALVAT
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bausch & Lomb Incorporated
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Kala Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Spectra Vision Care
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Alcon Laboratories
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AERIE PHARMACEUTICALS, INC.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Optocred Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- BRIM Biotechnology, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
8. Section
- Research Methodology
- About Us
02-2729-4219
+886-2-2729-4219
急性眼痛市場規模、佔有率和成長分析：按療法、藥物類別、適應症、給藥途徑、最終用戶、分銷管道和地區分類－2026-2033年產業預測
急性眼痛市場 - 全球及區域分析：按適應症、按區域 - 分析與預測（2025-2035 年）